ReviewFrontiers in oncology2022
FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging.Systematic reviews · 2025Pooled it
- Head-to-head comparison ofFrontiers in oncology · 2023Pooled it
- A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Survival benefit of ⁶⁸Ga-FAPI PET/CT staging for prognostic assessment in gastric and colorectal cancer compared with CE-CT and ¹⁸F-FDG PET/CT: a single-center retrospective study.European journal of nuclear medicine and molecular imaging · 2026Article
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- Is It time to move beyond FDG toward a more specific yet broadly applicable radiotracer such as FAPI? why yes-and why not.Annals of nuclear medicine · 2026Review
- The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [ 18 F] fluorodeoxyglucose PET.Nuclear medicine communications · 2026Article
- Preclinical evaluation of novelAnnals of nuclear medicine · 2026Article
- Per-patient Comparison of [Journal of Cancer · 2026Article
- Case Report: FAPI PET/CT detected occult contralateral DCIS and supraclavicular metastasis, guiding neoadjuvant therapy in synchronous bilateral breast cancer.Frontiers in oncology · 2026Article
- The comparative diagnostic and therapeutic application value of FAPI PET/CT andFrontiers in oncology · 2026Review
- Fibroblast activation protein-targeted radiopharmaceuticals: Recent trends in cancer diagnosis.Journal of clinical imaging science · 2026Review
- Enhanced contrast in FAP-targeting PET imaging withEJNMMI radiopharmacy and chemistry · 2025Article
- The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library.Communications biology · 2025Article
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Eliminating the second CT scan of dual-tracer total-body PET/CT via deep learning-based image synthesis and registration.European journal of nuclear medicine and molecular imaging · 2025Article
- Head-to-head comparison ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Unraveling the Role of PET in Cervical Cancer: Review of Current Applications and Future Horizons.Journal of imaging · 2025Review
- Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library.bioRxiv : the preprint server for biology · 2025Article
- PET in the characterization of immune diseases and development of therapeutics.Oxford open immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast activation protein (FAP), a type II transmembrane serine protease, is highly expressed in more than 90% of epithelial tumors and is closely associated with various tumor invasion, metastasis, and prognosis. Using FAP as a target, various FAP inhibitors (FAPIs) have been developed, most of which have nanomolar levels of FAP affinity and high selectivity and are used for positron emission tomography (PET) imaging of different tumors. We have conducted a systematic review of the available data; summarized the biological principles of FAPIs for PET imaging, the synthesis model, and metabolic characteristics of the radiotracer; and compared the respective values of FAPIs and the current mainstream tracer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.